ClinicalTrials.Veeva

Menu

Survivorship Intervention Program in Western Kenya: Study Protocol

M

Moi University

Status

Not yet enrolling

Conditions

Survivorship
Pediatric Cancer

Treatments

Behavioral: Educational Program (video, information booklet, Survivorship Card)
Behavioral: Follow-Up Program (form and healthcare provider training)

Study type

Interventional

Funder types

Other

Identifiers

NCT06680687
0004807

Details and patient eligibility

About

In this study protocol, the investigators described a survivorship intervention program that will be performed at a referral hospital in Western Kenya. This will be a non-randomized prospective cohort study with a sequential hybrid effectiveness - implementation design. The study comprises of an educational component for caregivers of childhood cancer survivors and a follow-up component targeting healthcare providers with survivorship training and implementation of a late effects documentation tool.

Through these interventions the investigators aim to:

  1. increase follow-up adherence of childhood cancer survivors;
  2. increase caregivers' and healthcare providers' knowledge about childhood cancer diagnoses, treatment and the corresponding late effects risks;
  3. document late effects at a childhood cancer outpatient clinic;
  4. evaluate program implementation and satisfaction among recipients and providers.

Full description

This non-randomized prospective cohort study will be performed at a referral hospital in Western Kenya. Hundred caregivers of children diagnosed with cancer, who will complete treatment within two months, will be enrolled and followed for 24 months after completion of treatment. A caregiver control group receiving usual care will be recruited and sequentially, caregivers will be included in an intervention group to attend an educational group session and receive educational materials (video, booklet and Survivorship Card). Primary study outcome will be survivors' follow-up adherence. Survivors will be considered lost to follow-up after missing a scheduled appointment and subsequently do not revisit the clinic for more than six months. Mixed models regression analyses will be performed to determine intervention effects on follow-up adherence and secondly on caregiver survivorship knowledge uptake. Additionally, healthcare providers will be trained on follow-up care, whereafter a form will be introduced at the outpatient clinic to document late effects in pediatric survivors attending the clinic for the period of a year. Secondary outcomes will be late effects prevalence as documented in the Follow-Up Form and healthcare provider survivorship knowledge uptake. Implementation measures (reach, potential effectiveness, adoption, satisfaction and maintenance) will be evaluated for both programs.

Enrollment

130 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Caregivers of children diagnosed with cancer (primary or secondary malignancy) below fifteen years old.
  • Children will soon be finalizing childhood cancer treatment (enrolled during the last 2 months of treatment).
  • Healthcare providers (the pediatric oncology workforce comprises of an estimated 30 staff members) working in the Pediatric Oncology department at MTRH will be recruited.
  • Any cadre involved in patient care or patient education (e.g. pediatric oncologists, fellows, registrars, medical officers, clinical officers, nurses, patient navigators, child life specialists) will be allowed to participate.

Exclusion criteria

  • Childhood cancer patients should have no treatment failure (abandonment, relapsed disease, progressive disease).
  • Caregivers of children with a relapsed malignancy in remission will be excluded.

Trial design

Primary purpose

Health Services Research

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

130 participants in 3 patient groups

"Usual Care"
No Intervention group
Description:
Participants receiving "Usual Care" group (A), will be recruited during the last two months of treatment (T-2). At the end of treatment (T0), participants will complete a knowledge questionnaire and will be followed for another 24 months. At six months after treatment completion (T6), a final follow-up knowledge assessment will be conducted. Participants will be enrolled into group A until the intended sample size of 50 participants is reached. Investigators estimated to have reached this number within four to six months based on recent survival rates.
"Educational Intervention"
Experimental group
Description:
A similar procedure will apply to the "Educational Intervention" group (B). Participants will complete a knowledge assessment before receiving an educational intervention between T-2 and T0. To evaluate early and late knowledge uptake, participants will complete a post-education knowledge assessment at T0 and a follow-up knowledge assessment at T6. Follow-up adherence will be evaluated at every three months for the first year and at every six months during the second year after treatment completion for both groups. Implementation measures will be captured starting at T3 until T24, together with a satisfaction questionnaire that will be administered at T6.
Treatment:
Behavioral: Educational Program (video, information booklet, Survivorship Card)
"Follow-Up Forms implementation"
Other group
Description:
Healthcare provider training on survivorship will start at the same timepoint as recruitment of the "Educational Intervention" group (A) at T-2. Follow-Up Forms will be introduced at the outpatient clinic once an estimated 30 healthcare providers have done the training (anticipated at T0). Healthcare providers will fill in a knowledge assessment directly pre- and post-training (T-2) and at six months post-training (T4). Documentation of late effect symptoms will be monitored for twelve months, starting at T0. Implementation measures will be collected weekly starting from T0 and healthcare providers will be assigned to a satisfaction questionnaire at T6.
Treatment:
Behavioral: Follow-Up Program (form and healthcare provider training)

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Susan Mageto, MPharm; Jesse Lemmen, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems